Skip to content
Question
What else lands on the bill?
Read
6 min
Published
September 2026

Peptide COA: What a Certificate of Analysis Proves, and What It Cannot

A certificate of analysis reports tests on one batch. Federal law requires one for bulk peptide used in compounding, and manufacturing rules show how far it can be trusted alone.

ByJenna PrattConsumer-access reporterPublished

A peptide COA is a document that reports what a laboratory found when it tested a specific batch: identity, purity, and sometimes content, water, endotoxin or sterility. It is only as good as the lab that ran the tests, the batch it describes, and whether that batch is the one in your hands. Any one of the three can fail.

On the licensed route, the COA is a starting document inside a regulated chain. On the research-use route, it may be the whole case for the product. The difference between those two is set out in the where-to-get-peptides guide.

Where the law requires one

A 503A pharmacy compounding from a bulk drug substance must use substances accompanied by valid certificates of analysis for each one[1]. The substance must also come from an establishment registered with FDA[1]. A 503B outsourcing facility has the same condition: each bulk substance must be accompanied by a valid certificate of analysis[2].

So a licensed pharmacy’s COA is a requirement on the raw material it buys, not a test of the finished vial it ships. What happens after the powder arrives depends on the tier, which is explained in 503A vs 503B.

How far a supplier’s COA is trusted in manufacturing

Drug manufacturers work under current good manufacturing practice, and the regulation on testing components is specific about supplier certificates. At least one test must verify the identity of each component[3]. A supplier’s report of analysis may stand in for the manufacturer’s own purity, strength and quality testing, but only on two conditions[3].

  • The manufacturer still runs at least one specific identity test itself.
  • The manufacturer establishes that the supplier’s analyses are reliable, by validating its results at appropriate intervals.

That is the regulator’s own answer to how much a COA proves on its own: enough to skip some repeat testing, never enough to skip checking identity or checking the supplier. Outsourcing facilities are held to these manufacturing standards; 503A pharmacies are not[4].

What to read on a certificate

If a seller offers a COA, a few lines tell you whether it describes anything you can rely on. None of them proves quality alone, and each one missing is a reason to ask more.

  • Lot or batch number, and whether it matches the number on the vial you received.
  • The laboratory’s name, and whether it is independent of the seller.
  • The test method for identity and for purity. A purity figure with no identity test does not show the peptide is the right one.
  • The test date, set against the product’s age. Peptides can degrade in storage.
  • Sterility and endotoxin results, for anything meant to be injected.

When the name on the paperwork is the problem

A certificate or label naming a real pharmacy does not prove that pharmacy made the product. FDA reports fraudulent compounded semaglutide and tirzepatide whose labels named pharmacies that do not exist, or licensed pharmacies that did not compound them[6]. The same risk applies to any document a seller supplies about its own product.

That is why the more useful question on the licensed route is not “can I see the COA” but “which pharmacy fills this, and is it licensed in my state.” A licensed pharmacy answers to a state board or to FDA; a certificate on its own answers to no one. Price comparisons for the licensed route are on the price boards, and the fees around them are in the peptide therapy cost guide.

FAQ

4 questions

What is a peptide COA?

A certificate of analysis: a document reporting a laboratory's test results for one batch of a substance, such as identity and purity.

Does a COA prove a peptide is safe?

No. It describes one batch as tested by the lab named on it. Federal manufacturing rules let a drugmaker rely on a supplier's report only after its own identity test and validation of the supplier.

Do compounding pharmacies need a certificate of analysis?

Yes. Federal law requires bulk drug substances used by 503A pharmacies and 503B outsourcing facilities to be accompanied by a valid certificate of analysis.

What should I check on a peptide COA?

The lot number against your vial, the lab's name and independence, the identity and purity methods, the test date, and sterility and endotoxin results for anything injected.

Sources

6 cited
  1. [1]United States Code (2013). 21 U.S.C. 353a, Pharmacy compounding (section 503A of the FD&C Act) Office of the Law Revision Counsel. Source
  2. [2]United States Code (2013). 21 U.S.C. 353b, Outsourcing facilities (section 503B of the FD&C Act) Office of the Law Revision Counsel. Source
  3. [3]Code of Federal Regulations (2026). 21 CFR 211.84, Testing and approval or rejection of components, drug product containers, and closures Electronic Code of Federal Regulations. Source
  4. [4]U.S. Food and Drug Administration (2025). Compounding and the FDA: Questions and Answers FDA, Human Drug Compounding. Source
  5. [5]Ashraf AR, Mackey TK, Vida RG, et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study Journal of Medical Internet Research. PMID 39509151
  6. [6]U.S. Food and Drug Administration (2026). FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA, Drug Alerts and Statements. Source